Supplementary figure: Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use

dataset

posted on 2024-05-03, 11:06 authored by David Kaplan, Elaine Husni, Eunice Chang, Michael Broder, Caleb Paydar, Kata Bognar, Jessie Yan, Sven Richter, Pooja Desai, Ibrahim Khilfeh

These are peer-reviewed supplementary materials for the article 'Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use' published in the Journal of Comparative Effectiveness Research.

Supplementary Figure 1: Time to biologic initiation during the 2-year follow-up period among patients with 2 years of follow-up
Supplementary Table 1: Patient demographic characteristics and prescriber specialty
Supplementary Table 2: Baseline comorbidities
Supplementary Table 3: Baseline medication use
Supplementary Table 4: Baseline healthcare utilization, and costs
Supplementary Table 5: Number of index medication fills before biologic initiation during the 1-year follow-up period
Supplementary Table 6: First biologic medication used during the 1-year follow-up period among apremilast patients who initiated biologic
Supplementary Table 7: First biologic medication used during the 1-year follow-up period among methotrexate patients who initiated biologic
Supplementary Table 8: Biologic initiation adjusted results

Aim: To compare rates of biologic initiation after commencing treatment with apremilast (APR) versus methotrexate (MTX) in systemic-naive patients with psoriasis (PsO). Methods: This was a retrospective cohort study of systemic-naive patients with PsO who initiated treatment with APR or MTX between 1 January 2015 and 31 March 2018. Outcomes: Adjusted rates of biologic initiation during follow-up were compared by logistic and Cox regressions. Results: APR initiators had 58% lower likelihood of biologic initiation (odds ratio: 0.42; 95% CI: 0.37–0.48; p < 0.001), lower adjusted biologic initiation rate (14.4% [95% CI: 13.2–15.7%] vs 28.6% [95% CI: 26.8–30.5%]), lower risk of biologic initiation (hazard ratio: 0.45; 95% CI: 0.40–0.51; p < 0.001) compared with MTX initiators. Conclusion: Systemic-naive patients with PsO have a lower rate of biologic initiation over 1 year following APR initiation.